Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
13 nov. 2018 07h27 HE
|
Aptinyx Inc.
Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in humans Plan to...
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans
12 nov. 2018 07h07 HE
|
Aptinyx Inc.
Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage...
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
01 nov. 2018 07h27 HE
|
Aptinyx Inc.
Top-line Data Expected Early in the First Quarter of 2019 EVANSTON, Ill., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing...
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience
29 oct. 2018 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference
25 sept. 2018 16h01 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system...
Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain
14 sept. 2018 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
21 août 2018 06h35 HE
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports Second Quarter 2018 Financial and Business Results
14 août 2018 06h27 HE
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Initiates Phase 1 Study of NYX-458
02 août 2018 08h00 HE
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...